Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo
Open Access
- 23 March 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (3) , e0281063
Abstract
Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS). Because directly targeting most mutations of RAS is technically challenging, researchers have concentrated on targeting MEK, a downstream mediator of RAS. However, targeting MEK as single-agent therapy is ineffective in patients with mCRC. We hypothesize that combining a MEK inhibitor with other agents can enhance the efficacy of MEK targeting in mCRC. Unbiased high-throughput screening (HTS) was performed to identify drugs that enhance the efficacy of MEK inhibitors. HTS was performed with KRAS-mutated CRC cells using the MEK inhibitor trametinib as a “backbone” and two “clinically ready” compound libraries approved by the U.S. Food and Drug Administration or in clinical trials. HTS demonstrated that the combination of the SRC inhibitor dasatinib and trametinib was synergistic in CRC cells in vitro (MTT and colony formation assays). Analysis of markers for cell proliferation and apoptosis using fluorescence-activated cell sorting, reverse-phase protein array, or Western blotting demonstrated decreased cell proliferation and increased cell death when targeting both SRC and MEK as compared to single agents in multiple CRC cell lines. However, combining dasatinib and trametinib in vivo at doses in mice equivalent to doses used in humans failed to significantly enhance the antitumor activity of trametinib when compared to that of trametinib alone. These results underscore the importance of performing careful preclinical in vivo validation studies using clinically relevant doses as a prerequisite for translating in vitro findings to the clinic.Keywords
Funding Information
- DOD Peer Reviewed Cancer Research Program (CA181043)
- DOD Peer Reviewed Cancer Research Program (CA140515)
- Cancer Prevention and Research Institute of Texas (RP150578)
- Cancer Prevention and Research Institute of Texas (RP110532)
This publication has 61 references indexed in Scilit:
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerNew England Journal of Medicine, 2013
- Recurrent R-spondin fusions in colon cancerNature, 2012
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature, 2012
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation StatusJournal of Clinical Oncology, 2011
- Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II ConsortiumInvestigational New Drugs, 2011
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancerBritish Journal of Cancer, 2011
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerBritish Journal of Cancer, 2009
- Molecular Basis for Class V β-Tubulin Effects on Microtubule Assembly and Paclitaxel ResistanceJournal of Biological Chemistry, 2009
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Combined Inhibition of MEK and mTOR Signaling Inhibits Initiation and Progression of Colorectal CancerCancer Investigation, 2009